A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.

Trial Profile

A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs THV 02 (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors THERAVECTYS
  • Most Recent Events

    • 12 Feb 2015 New trial record
    • 04 Feb 2015 According to Theravectys media release, European Medicines Agency (EMA) has granted Orphan Drug Designation to THV02 for the treatment of adult T-cell leukemia/lymphoma.
    • 04 Feb 2015 According to Theravectys media release, recruitment is planned to begin at the end of Q3 2015 in Europe and further proceed to the U.S and Japan in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top